Search results
Showing 1096 to 1110 of 2107 results for technology appraisal
Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.
This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS93Show all sections
Sections for QS93
- Quality statements
- Quality statement 1: Anticoagulation to reduce stroke risk
- Quality statement 2: Use of aspirin
- Quality statement 3: Discussing options for anticoagulation
- Quality statement 4: Anticoagulation control
- Quality statement 5: Referral for specialised management
- Quality statement 6 (developmental): Self-monitoring of anticoagulation
- Update information
Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)
This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]
Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)
This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314].
Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.